1.Reducing the overuse and misuse of antimi crobials, including antibiotics
2.Implementing robust prevention measures including improved cleanliness in hospitals
3.Improving surveillance and monitoring in humans and animals
4.Developing new effective treatments
Developing new classes of antibiotics that can tackle the issue of microbial resistance is a particular challenge. Over the last two decades, there have been few novel antibiotics approved by health authorities and of these a very small proportion can be identified as having a truly novel mechanism of action. Therefore, it has become increasingly important to explore ways to restore the effectiveness of antibacterial agents that were highly effective prior to the evolution of emerging resistance mechanisms. This approach is particularly appropriate for the class of β-lactam antibiotics. β-lactam antibiotics include penicillins, cephalosporins and
carbapenems, which have been a mainstay of antibacterial treatment for many years, saving countless lives and transforming the practice of modern medicine. However,due to their widespread use and subsequent emergence of specific resistance mechanisms, β-lactam antibiotics are becoming much less effective against many important pathogens. Successful strategies that restore the effectiveness of β-lactam antibiotics include the co-administration of a β-lactamase inhibitor (BLI) together with an antibiotic. BLIs are compounds that inhibit the action of β-lactamases, the enzymes produced by some bacteria that make them resistant to certain antibiotics. Allecra is developing an extended spectrum BLI that restores the effectiveness of cefepime, a powerful antibiotic, even in the face of some potent, emerging, β-lactamase mediated resistance mechanisms. Allecra’s extended spectrum BLI is known as Enmetazobactam and it is currently in Phase 3 clinical trials
1. World Health Organization Factsheet 194. Available at www.who.int/mediacentre/factsheets/fs194/en.
2. Review on Antimicrobial Resistance. www.amr-review.org.